Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been given a $109.00 price objective by stock analysts at Jefferies Group in a research note issued on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price indicates a potential upside of 33.86% from the stock’s previous close.

A number of other equities analysts have also weighed in on RARE. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $69.00 price target on the stock in a research report on Thursday, October 20th. Credit Suisse Group AG reissued a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 14th. Piper Jaffray Cos. set a $82.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Wedbush reissued an “outperform” rating and set a $92.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $94.00 price target (up previously from $85.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $94.23.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 81.43 on Monday. The stock has a 50 day moving average of $66.94 and a 200 day moving average of $63.82. Ultragenyx Pharmaceutical has a 1-year low of $46.52 and a 1-year high of $117.12. The stock’s market cap is $3.33 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.53) by $0.11. During the same period in the prior year, the company posted ($1.03) earnings per share. Equities analysts expect that Ultragenyx Pharmaceutical will post ($6.14) earnings per share for the current year.

In related news, CFO Shalini Sharp sold 12,000 shares of the firm’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $61.40, for a total transaction of $736,800.00. Following the completion of the transaction, the chief financial officer now directly owns 57,387 shares of the company’s stock, valued at approximately $3,523,561.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Friday, October 14th. The stock was sold at an average price of $63.02, for a total value of $1,260,400.00. Following the transaction, the chief executive officer now directly owns 480,632 shares of the company’s stock, valued at $30,289,428.64. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its position in shares of Ultragenyx Pharmaceutical by 45.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 483,500 shares of the biopharmaceutical company’s stock valued at $30,610,000 after buying an additional 150,000 shares in the last quarter. State Street Corp raised its position in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock valued at $81,315,000 after buying an additional 300,901 shares in the last quarter. CAM Group Holding A S raised its position in shares of Ultragenyx Pharmaceutical by 52.5% in the second quarter. CAM Group Holding A S now owns 61,000 shares of the biopharmaceutical company’s stock valued at $2,984,000 after buying an additional 21,000 shares in the last quarter. Princeton Alpha Management LP bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $216,000. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Ultragenyx Pharmaceutical by 222.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 59,720 shares of the biopharmaceutical company’s stock valued at $2,971,000 after buying an additional 41,200 shares in the last quarter. 93.01% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.